GlassScriptPhysician profile
Gabrielle Ann Peterman
NPI 1396367165
$1,932.20
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,340 · 2022: $134 · 2023: $231 · 2024: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $458.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $413.96 | 2021-2022 | |
| Janssen Biotech, INC. | $283.95 | 2021-2024 | Tecvayli, Darzalex, Carvykti |
| Amgen INC. | $222.30 | 2021 | |
| Glaxosmithkline, LLC. | $125.00 | 2023 | Jemperli |
| Beigene USA, INC. | $97.42 | 2024 | Brukinsa |
| Incyte Corporation | $77.99 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $75.05 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $66.29 | 2021 | |
| Sanofi-Aventis U.S. LLC | $64.99 | 2021 | |
| Daiichi Sankyo INC. | $62.76 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $50.63 | 2021 | |
| Eisai INC. | $39.77 | 2021 | |
| Acrotech Biopharma INC. | $33.74 | 2021 | |
| Jazz Pharmaceuticals INC. | $33.42 | 2021 | |
| Exelixis INC. | $31.63 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $30.17 | 2021 | |
| Pfizer INC. | $28.27 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $23.63 | 2021 | |
| Emd Serono, INC. | $19.40 | 2021 | |
| Kyowa Kirin, INC. | $18.91 | 2021 | |
| Genzyme Corporation | $18.19 | 2021 | |
| Merck Sharp & Dohme LLC | $18.02 | 2021 | |
| Abbvie INC. | $17.02 | 2024 | |
| Alexion Pharmaceuticals, INC. | $15.89 | 2021 | |
| Genentech USA, INC. | $14.76 | 2021 | |
| Global Blood Therapeutics, INC. | $13.49 | 2021 | |
| Pharmacosmos Therapeutics INC. | $12.91 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $11.58 | 2021 | |
| Astellas Pharma US INC | $11.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabrielle Peterman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.